Stay updated on MAPP2 MDMA Therapy Clinical Trial
Sign up to get notified when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.

Latest updates to the MAPP2 MDMA Therapy Clinical Trial page
- CheckyesterdayChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check8 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1, while the page remains a 403 error screen.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedAccess to the study record is blocked by a 403 Forbidden page, replacing the usual study content and documents with a generic error screen.SummaryDifference19%

- Check36 days agoChange DetectedIsrael locations list updated: Tel Litwinsky, Israel added as a participating site and Qiryat Krinitzi, Israel removed.SummaryDifference0.1%

- Check43 days agoChange DetectedThe addition of Qiryat Krinitzi, Israel as a study site expands the list of locations for participant enrollment. Tel Litwinsky, Israel has been removed from the list of participating sites.SummaryDifference0.1%

- Check50 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6, indicating a small page version update. No changes to the study content or data are indicated.SummaryDifference0.1%

Stay in the know with updates to MAPP2 MDMA Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.